Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Study of Resencatinib (HS-10365) in Subjects with Hepatic Impairment
NCT06823258Phase 1Not yet recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Feb 2025
- Primary completion
- Jul 2025
01
Overview
Phase 1, open-label trial of resencatinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Hansoh Pharmaceutical Group. Primary endpoints: Peak Plasma Concentration, Area Under the Curve from time zero to last measurable concentration and 1 more. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
resencatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06823258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06823258.